2024-515853-48-00招募中3 期
A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-small cell lung cancer
Mabxience Research S.L.60 个研究点 分布在 9 个国家目标入组 269 人开始时间: 2025年3月25日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 269
- 试验地点
- 60
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years(65+ Years, 18-64 Years)
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Susana Millán
Scientific
Mabxience Research S.L.
研究点 (60)
Loading locations...
相似试验
招募中
4 期
A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected MelanomaMelanoma2025-522307-14-00Intas Pharmaceuticals Limited19
已完成
1 期
Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR2023-507667-19-00Novartis Pharma AG24
已完成
1 期
A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with hepatic impairment compared to matched control participants with normal hepatic functionUrticariaAllergic rhinitis2022-500774-34-00Noucor Health S.A.44
招募中
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination with Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors2023-504709-35-00Genentech Inc.44
招募中
1 期
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination with Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma2023-505212-38-00Genentech Inc.43
